MARKET

CAI

CAI

Caris Life Sciences, Inc.
NASDAQ
16.95
-1.38
-7.53%
After Hours: 16.80 -0.15 -0.89% 18:41 03/27 EDT
OPEN
18.12
PREV CLOSE
18.33
HIGH
18.29
LOW
16.43
VOLUME
3.71M
TURNOVER
--
52 WEEK HIGH
42.50
52 WEEK LOW
16.43
MARKET CAP
4.79B
P/E (TTM)
-5.2684
1D
5D
1M
3M
1Y
5Y
1D
Caris Life Sciences adds two AI signatures predicting brain metastases risk in breast and lung cancer; study progresses on 12,994 NSCLC cases and 3,371 breast cancer cases
Reuters · 2d ago
Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
PR Newswire · 2d ago
Caris Life Sciences announces six oncology studies for AACR 2026; research focus expands across breast, prostate, lung, and colorectal cancers
Reuters · 3d ago
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
PR Newswire · 3d ago
Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month
PR Newswire · 4d ago
Weekly Report: what happened at CAI last week (0316-0320)?
Weekly Report · 5d ago
Caris Life Sciences Publishes Supporting Evidence For AI-Based Cancer Diagnosis
Benzinga · 03/20 12:40
Caris Life Sciences announces publication of study on GPSai algorithm
TipRanks · 03/20 12:35
More
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Webull offers Caris Life Sciences, Inc. stock information, including NASDAQ: CAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAI stock methods without spending real money on the virtual paper trading platform.